NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation

Ming Xiong1, Liang Chen1, Lijie Zhou1

  • 1Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Theranostics
|November 8, 2019
PubMed

Insights

Nudix Hydrolase 21 (NUDT21) is reduced in bladder cancer, suppressing tumor growth. Lower NUDT21 levels correlate with poorer survival, suggesting its potential as a diagnostic and therapeutic target for bladder cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Nudix Hydrolase 21 (NUDT21) is a key regulator of alternative polyadenylation (APA).
  • NUDT21 functions as a tumor suppressor in various human cancers.
  • The specific role and mechanisms of NUDT21 in bladder cancer (BC) remain unexplored.

Purpose of the Study:

  • To investigate the role of NUDT21 in bladder cancer (BC) progression.
  • To elucidate the underlying molecular mechanisms by which NUDT21 influences BC tumorigenesis.
  • To evaluate NUDT21 as a potential diagnostic and therapeutic target for BC.

Main Methods:

  • Real-time PCR, western blotting, and immunohistochemistry (IHC) assessed NUDT21 expression in BC.
  • In vitro and in vivo assays evaluated NUDT21's functional impact on BC cell proliferation, migration, and invasion.
  • TOP/FOP flash assays, western blot, and global APA profiling identified NUDT21-mediated pathways, including Wnt/β-catenin and NF-κB signaling via ANXA2 and LIMK2.

Main Results:

  • NUDT21 expression was significantly reduced in BC tissues and cells compared to normal controls.
  • Lower NUDT21 expression in BC patients correlated with shorter overall and recurrence-free survival.
  • NUDT21 manipulation affected BC cell proliferation, migration, and invasion; identified ANXA2 and LIMK2 as key regulated genes.

Conclusions:

  • NUDT21 acts as a tumor suppressor in bladder cancer, inhibiting progression.
  • NUDT21 regulates BC progression partly through ANXA2 and LIMK2 via alternative polyadenylation.
  • NUDT21 presents a promising diagnostic and therapeutic target for bladder cancer treatment.